Vaitris, Inc. VTRS has announced that it has reached a settlement framework nationwide to solve the state, local government and tribal opioids.
According to the consensus contract conditions, Viatris pays up to $ 355 million to all mentioned above. This amount consists of annual payments of about $ 27.5 to $ 40 million for nine years to support the state and local efforts to solve the opioid -related problems.
But Viaatris said the agreement was never a fault or a position of responsibility.
VTRS’s share price has plummeted 38.1% to date compared to the 4.6% decrease in the industry.
Image Source: ZACKS Investment Research
Viaatris is a defendant submitted by a variety of manuscripts that pursue damage and relief in more than 1,000 cases of the United States and Canada, along with other manufacturers, distributors, pharmacies, pharmacies, pharmacy benefits managers and individual medical service providers.
VTR and many other pharmaceutical companies have been accused of not stating the health risk of Opioid -related drugs.
In addition, the lawsuit was filed as an estimated group behavior, including the children of the newborn abstinence syndrome due to the exposure to opioids.
Viaatris has generated about $ 270 million as of December 31, 2024, which is included in other current debt in the integrated loan schedule in relation to certain solutions of these problems.
Viaatris was formed through the merger of MyLan. PfizerPFE UPJOHN Business.
Since 2019, the company has agreed to pay PFIZER about about 57%of the predecessor, predecessor or subsidiary’s losses, and is caused by third -party measures regarding the manufacture, distribution, marketing, promotion or sales of OPIOIDs on behalf of ViaATRIS, predecessor or subsidiary.
VTRS is a general injectable version of Nillock Son, a general bouquet frennorpin/nail hand product that is currently used for the treatment of opioid addiction. We are also developing new delivery to Meloxicam, a non -opioid painkiller.
In February, VTRS reported the results lower than expected, where the top and conclusions missed each estimates. The land of 2025 was also disappointing.
Viaatris Inc. Price-Consensus-EPS-SURPRISE-Chart | Vaitris Inc. estimate
